I don’t think management want to beach the duty of continuous disclosure. It’s likely they don’t care much about what they think is insignificant progress. There’s investor presentation from time to time but haven’t seen that for a while. We certainly can email to remind the board they need to at least update FDA trial and data analysis on par with other listed company. It will even be better if they can include sales achievement in timely manner.
Ann: Genetic Signatures completes $35m placement, page-10
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $175.5M | |||
| Open | High | Low | Value | Volume |
| 76.0¢ | 78.0¢ | 76.0¢ | $127.2K | 164.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19491 | 76.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 77.5¢ | 170702 | 2 |
View Market Depth
| Last trade - 15.44pm 18/07/2024 (20 minute delay) ? |
| GSS (ASX) Chart |